Status:
COMPLETED
An Observational Study of the Safety and Effectiveness of Galantamine in the Treatment of Patients With Alzheimer's Disease Over an 18-month Period
Lead Sponsor:
Janssen-Cilag Pty Ltd
Conditions:
Alzheimer Disease
Dementia
Eligibility:
All Genders
Brief Summary
The purpose of this observational study is to investigate the changes in cognitive functioning, behavior, and functional improvement in Alzheimer's disease patients treated with Galantamine who are li...
Detailed Description
This is a prospective, observational study to assess the changes in cognitive functioning, behavior, and functional improvement in Alzheimer's disease patients treated with Galantamine who are living ...
Eligibility Criteria
Inclusion
- Patients prescribed with galantamine according to the approved New Zealand Data Sheet
- The clinical decision to prescribe Galantamine must have been made before and independently of the decision to enroll the patient in this observational study
- The patient should not have commenced Galantamine treatment before the baseline visit
- Patients must be currently living at home (i.e. not in permanent residential care)
- Availability of a supporter who has regular contact with the patient
Exclusion
- Patients having known hypersensitivity to Galantamine
- Having severe liver impairment or severe kidney impairment
- Suffering from an uncontrolled medical condition other than dementia
- Being treated, or previously treated, with another cholinesterase inhibitor or other cholinomimetics (medications for treating Alzheimer's disease)
Key Trial Info
Start Date :
May 1 2005
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
March 1 2008
Estimated Enrollment :
61 Patients enrolled
Trial Details
Trial ID
NCT00299676
Start Date
May 1 2005
End Date
March 1 2008
Last Update
May 23 2014
Active Locations (5)
Enter a location and click search to find clinical trials sorted by distance.
1
Auckland, Australia
2
Christchurch Nz, Australia
3
Hamilton, Australia
4
Porirua, Australia